Some lengthy COVID sufferers nonetheless have virus within the blood; Paxlovid rebound sufferers may have longer remedy

A healthcare employee collects a swab from a passenger for a PCR check towards the coronavirus illness (COVID-19) earlier than touring to Uganda, amidst the unfold of the brand new SARS-CoV-2 variant Omicron, at O.R. Tambo International Airport in Johannesburg, South Africa, November 28, 2021. REUTERS/ Sumaya Hisham/File Photo

Register now for FREE limitless entry to Reuters.com

June 23 (Reuters) – The following is a abstract of some latest research on COVID-19. They embrace analysis that warrants additional research to corroborate the findings and that has but to be licensed by peer assessment.

Some lengthy COVID sufferers nonetheless have virus in blood

Some instances of lengthy COVID will be the immune system’s response to a SARS-CoV-2 an infection lurking someplace within the physique, new findings from a small research recommend.

Register now for FREE limitless entry to Reuters.com

Researchers analyzed a number of plasma samples collected over time from 63 sufferers with COVID-19, together with 37 who went on to develop lengthy COVID. In the vast majority of these with lengthy COVID, the spike protein from the floor of the virus was detectable for as much as 12 months, whereas it was not current in plasma samples from recovered sufferers with out lasting signs. Spike protein circulating within the blood may imply “a reservoir of active virus persists in the body,” the researchers stated in a paper posted on medRxiv final week forward of peer assessment. Exactly the place that reservoir is perhaps just isn’t clear from this research. Researchers stated they’ve beforehand discovered energetic virus within the gastrointestinal tract of kids weeks after the preliminary coronavirus an infection, and different researchers have discovered genetic proof of the virus “in multiple anatomic sites up to seven months after symptom onset.”

If the outcomes may be confirmed in bigger research, the presence of spike protein within the blood lengthy after the preliminary an infection could also be one strategy to diagnose lengthy COVID, the researchers stated.

Paxlovid “rebound” sufferers may have longer remedy

The rebound of signs reported in some COVID-19 sufferers who took a five-day course of Pfizer’s antiviral Paxlovid drugs could also be the results of inadequate remedy, in line with researchers who intently evaluated one such affected person.

Trial outcomes confirmed that Paxlovid can scale back the chance of hospitalization and dying from COVID-19 in high-risk sufferers by 89% if taken inside 5 days of symptom onset. In some sufferers, nonetheless, virus ranges and signs have rebounded after finishing a course of Paxlovid, resulting in considerations that variants is perhaps growing resistance to the two-drug remedy or that the drugs might someway be weakening sufferers’ antibody resistance. But when researchers remoted the Omicron BA.2 variant from a rebound affected person and examined it in lab experiments, they discovered it was nonetheless delicate to Paxlovid and had no mutations that would cut back the drug’s effectiveness. They additionally discovered their affected person’s antibodies may nonetheless block the virus from getting into and infecting new cells.

The rebound of COVID-19 signs after Paxlovid remedy is probably going occurring as a result of not sufficient of the drug is reaching contaminated cells to utterly cease the virus from making copies of itself, the researchers stated in a paper printed on Monday in Clinical Infectious Diseases. It can be attainable that the drug could also be metabolized, or processed, at completely different charges in numerous folks, or that some folks have to take it for greater than 5 days.

After COVID-19, youngsters have extra signs however much less anxiousness

Persistent well being issues had been solely barely extra widespread in youngsters after COVID-19 than in similarly-aged youngsters who prevented the virus, researchers from Denmark reported on Wednesday in The Lancet Child & Adolescent Health. Anxiety ranges, nonetheless, had been larger in youngsters who by no means had COVID-19, the researchers additionally discovered.

They stated 40% of infants and toddlers with COVID-19 and 27% of their uninfected friends skilled at the very least one symptom for greater than two months. Among youngsters ages 4 to 11, persistent signs had been seen in 38% with COVID-19 and 34% with out it. And amongst 12- to 14-year-olds, 46% of these with COVID-19 and 41% of these with out it had long-lasting signs. The outcomes had been based mostly on a survey of practically 11,000 moms of contaminated youngsters and practically 33,000 moms of uninfected youngsters.

While signs related to lengthy COVID equivalent to headache, temper swings, belly ache and fatigue are sometimes skilled by in any other case wholesome youngsters, contaminated youngsters had longer-lasting signs and one-third had new signs that developed after COVID-19. To the researchers’ shock, youngsters who had COVID-19 skilled fewer psychological and social issues than these within the management group. They speculated this can be as a result of the uninfected youngsters had extra “fear of the unknown disease and more restricted everyday life due to protecting themselves from catching the virus.”

Click for a Reuters graphic on vaccines in growth.

Register now for FREE limitless entry to Reuters.com

Reporting by Nancy Lapid; Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Leave a Comment